Literature DB >> 12488239

Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health.

Heather J Chial1, Michael Camilleri, Duane Burton, George Thomforde, Kevin W Olden, Debra Stephens.   

Abstract

This study evaluated the effects of serotonergic psychoactive agents on gastrointestinal functions in healthy human subjects. Participants received one of four regimens in a randomized, double-blind manner: buspirone, a 5-HT(1A) receptor agonist (10 mg twice daily); paroxetine, a selective serotonin reuptake inhibitor (20 mg daily); venlafaxine-XR, a selective serotonin and norepinephrine reuptake inhibitor (75 mg daily); or placebo for 11 days. Physiological testing performed on days 8-11 included scintigraphic assessment of gastrointestinal and colonic transit, the nutrient drink test, and assessment of the postprandial change in gastric volume. Fifty-one healthy adults (40 females, 11 males) participated in this study. No effects on gastric emptying or colonic transit were identified with any agent. Small bowel transit of a solid meal was accelerated by paroxetine. Buspirone decreased postprandial aggregate symptom and nausea scores. Venlafaxine-XR increased the postprandial change in gastric volume. Buspirone, paroxetine, and venlafaxine-XR affect upper gastrointestinal functions in healthy humans. These data support the need for clinical and physiological studies of these agents in functional gastrointestinal disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12488239     DOI: 10.1152/ajpgi.00266.2002

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  39 in total

Review 1.  Pharmacology of serotonin: what a clinician should know.

Authors:  F De Ponti
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

Review 2.  Treating irritable bowel syndrome: overview, perspective and future therapies.

Authors:  Michael Camilleri
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

3.  Is the antidepressant venlafaxine effective for the treatment of functional dyspepsia?

Authors:  Lukas Van Oudenhove; Jan Tack
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-12-17

Review 4.  Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.

Authors:  Michael Camilleri; Lin Chang
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

5.  Gastric motor disturbances in patients with idiopathic rapid gastric emptying.

Authors:  A E Bharucha; A Manduca; D S Lake; J Fidler; P Edwards; R C Grimm; A R Zinsmeister; S J Riederer
Journal:  Neurogastroenterol Motil       Date:  2011-04-06       Impact factor: 3.598

Review 6.  Current and emerging pharmacotherapeutic options for irritable bowel syndrome.

Authors:  Jose L Barboza; Nicholas J Talley; Baharak Moshiree
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 7.  Gut Movements: A Review of the Physiology of Gastrointestinal Transit.

Authors:  Dennis Kumral; Alvin M Zfass
Journal:  Dig Dis Sci       Date:  2018-10       Impact factor: 3.199

8.  Treatment of Functional GI Disorders With Psychotropic Medicines: A Review of Evidence With a Practical Approach.

Authors:  Syed I M Thiwan; Douglas A Drossman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-09

9.  Current and emerging therapies for the management of functional gastrointestinal disorders.

Authors:  Orla F Craig; Eamonn M M Quigley
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

Review 10.  Current management strategies and emerging treatments for functional dyspepsia.

Authors:  Michael Camilleri; Vincenzo Stanghellini
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-05       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.